Back to search
A Study to Evaluate Preventive Treatments for Talquetamab-related Oral Toxicity
Refractory Multiple Myeloma
Relapse Multiple Myeloma
Clinicaltrials.gov:
EU CTIS:
#2023-506260-14-00
Other:
#64407564MMY2006
Trials at a glance
Status
Enrolling
Condition
Refractory Multiple Myeloma
Relapse Multiple Myeloma
Trial type
Interventional
Trial phase
Phase 2
Investigational
product
product
Prophylaxis A
Prophylaxis B
Prophylaxis C
Talquetamab
Age
18+ years old
Biological sex
All
Placebo?
No
Trial start date
August 26, 2024
Trial end date
April 30, 2029
CT.gov ID
#NCT06500884
Share the trial ID with your doctor to see if trial participation is right for you. Participation depends on an independent medical assessment.
Countries:
- Brazil,
- Netherlands,
- Puerto Rico,
- South Korea,
- Spain,
- United Kingdom,
- United States
Loading...
Enrolling
Dordrecht, Netherlands, 3318 AT
Enrolling
Belfast, United Kingdom, BT9 7AB
Enrolling
São Paulo, Brazil, 01455 010
Enrolling
Colchester, United Kingdom, CO4 5JL
Enrolling
Denver, Colorado, United States, 80218
Enrolling
Durham, North Carolina, United States, 27705
Enrolling
Eastbourne, United Kingdom, BN21 2UD
Enrolling
Rotterdam, Netherlands, 3015 CN
Enrolling
Caxias do Sul, Brazil, 95070 560
Enrolling
London, United Kingdom, W12 0HS
Enrolling
Barcelona, Spain, 08036
Enrolling
Salamanca, Spain, 37007
Enrolling
Pozuelo de Alarcón, Spain, 28223
Enrolling
Madrid, Spain, 28041
Enrolling
Badalona, Spain, 08916
Enrolling
Madrid, Spain, 28034
Enrolling
El Palmar, Spain, 30120
Enrolling
Jerez de la Frontera, Spain, 11407
Enrolling
Brasília, Brazil, 70390-140
Enrolling
Curitiba, Brazil, 81520-060
Enrolling
San Juan, Puerto Rico, 00918
Enrolling
New York, New York, United States, 10029
Enrolling
Salvador, Brazil, 41253 190
Enrolling
São Paulo, Brazil, 04543-000
Enrolling
Newcastle upon Tyne, United Kingdom, NE7 7DN
Enrolling
Seoul, South Korea, 135-230
Enrolling
Seoul, South Korea, 03080
Enrolling
Seoul, South Korea, 06591
Enrolling
Manchester, United Kingdom, M20 4BX
Enrolling
Liverpool, United Kingdom, L7 8YA
Enrolling
London, United Kingdom, NW1 2BU
Enrolling
Cleveland, Ohio, United States, 44106
Enrolling
San Francisco, California, United States, 94143
Enrolling
Rochester, New York, United States, 14642
Enrolling
Seattle, Washington, United States, 98109
Enrolling
Amsterdam, Netherlands, 1081 HV
Enrolling
Richmond, Virginia, United States, 23298
Enrolling
New Haven, Connecticut, United States, 06510
#
More than 50 sites in this region
#
More than 10 sites in this region
#
Less than 10 sites in this region
Individual sites
Access detailed information on the trial:
Clinical trials information
© Johnson & Johnson and its affiliates 2026
